Se faire rembourser son CBD par la Sécurité Sociale, un rêve encore lointain ?

Getting your CBD reimbursed by the social security system: still a distant dream?

Unlike THC and its recreational use, CBD is mainly taken for the therapeutic properties it is believed to have on the body. Most occasional or regular CBD consumers therefore aim to ease a symptom or improve a specific condition. This raises the question of whether CBD products are reimbursed by French Social Security.

To separate fact from fiction, here’s a summary of the relationship between CBD, French Social Security, private health insurance and the concept of medicinal cannabis.

Can a doctor prescribe CBD?


Although CBD is popular for its purported relaxing and generally calming properties, no, a doctor cannot prescribe CBD. Only conventional medicines officially recognised as such can be prescribed, and CBD does not fall into this category.


No, CBD products are not reimbursed by French Social Security


As mentioned in the previous section, CBD is not considered a medicine and is therefore not reimbursed by the French Social Security system.

It is true that cannabidiol has been legalised throughout France and that its effects are reputed to be particularly beneficial for all types of consumers. However, the legalisation of CBD does not mean that it has been legally recognised as having therapeutic properties. As a result, CBD products are not eligible for reimbursement by the public Social Security system, which remains reserved for officially recognised medicines and treatments.


Even so, CBD’s purported health benefits are appealing. Very appealing. As for its pain-relieving properties, taking CBD could significantly reduce chronic pain, and may even ease the symptoms of various serious conditions. One example is cervical osteoarthritis, whose painful joint symptoms may be eased with CBD. Another striking example is epilepsy. Regular CBD use could potentially slow cell deterioration, as well as significantly reduce inflammation in the brain, which is said to contribute to the progression and worsening of the condition. In time, these factors could lead French Social Security to reconsider cannabidiol’s therapeutic status.


What about reimbursement by private health insurance?


Reimbursement for CBD products by French Social Security is entirely out of the question. But what about private health insurance? In particular, could it help with smoking cessation?


CBD is indeed recognised as an effective way to tackle tobacco dependence. When it comes to smoking cessation, it’s worth knowing that the French health insurance system covers only a tiny proportion of the costs. As a result, only nicotine replacement products prescribed by a doctor are reimbursed, and only in part. E-liquids, however, fall outside the scope of any potential reimbursement, whether or not they contain CBD.


One option is to take out private supplementary health insurance in the hope that it will agree to cover CBD products used to help quit smoking. In practice, this could take the form of an annual allowance. However, you should check that the insurer does cover CBD-based e-liquids, rather than just nicotine-based ones.


Could medicinal cannabis be reimbursed?


Medicinal cannabis is a widely used term in some other countries, such as the United States, but the situation in France is quite different. The ANSM is the relevant authority in this area. It considers that, because of the harmful effects associated with burning CBD, or medicinal cannabis, it cannot be authorised for consumption by smoking. 


Other methods of consumption remain tolerated, such as CBD oils, e-liquids and extracts.

The year 2019 nevertheless marked a shift in attitudes in Europe. That year, many MEPs publicly expressed their intention to draw a clear distinction between recreational cannabis, cannabis for medical and therapeutic use, and CBD products. 


Shortly afterwards, on 13 February 2019, the European Parliament made headlines by voting on a landmark resolution: to support research into medicinal cannabis and establish uniform standards for what is known as medical cannabis and CBD.


For now, some private health insurers agree to reimburse everyday products such as e-liquids, on the grounds that they form part of a therapeutic treatment. However, this interpretation varies from one insurer to another and does not reflect the general position of the French Social Security system.

Consumers nevertheless remain optimistic that medicinal cannabis will be officially recognised and that CBD will become eligible for reimbursement by French Social Security. Medicines containing CBD have already been granted marketing authorisations and are regularly prescribed. However, these are still exceptions, and there is a long way to go before medicinal cannabis becomes widely accepted.